CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .
Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?
Objective To assess the discriminative ability and correlation of the Ankylosing Spondylitis Disease Activity Score ( ASDAS ) and Bath Ankylosing Spondylitis Activity Disease Activity Index ( BASDAI ) with disease activity in axial psoriatic arthritis ( AxPsA ) . Methods Patients with AxPsA were selected from a large prospect i ve cohort study of psoriatic arthritis . Patient and physician global scores were used as constructs of disease activity . Patients were categorised into high and low disease activity states based on patient and physician global assessment scores and physician 's decision to change treatment . Statistical analysis included descriptive statistics , linear and logistic regression . Results 201 patients with AxPsA were included in the study . ASDAS and BASDAI showed good correlation with disease activity as reflected by the patient global score ( correlation coefficients ( r ) for BASDAI 0.84 , ASDAS-B 0.77 , ASDAS-C 0.81 , p<0.001 ) and the physician global score ( r=0.53 for BASDAI , r=0.50 for ASDAS-B , r=0.55 for ASDAS-C , p<0.001 ) . Both scores showed good discriminative ability between high and low disease activity states . However , there were no significant differences between areas under the curve for the models that compared ASDAS with BASDAI for each definition of disease activity state . Conclusions In patients with AxPsA , ASDAS and BASDAI scores show similar good to moderate discriminative ability and correlation with different constructs of disease activity . ASDAS was not superior to BASDAI in its ability to discriminate between high and low disease activity states in
CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .